The Nanoparticle Drug Delivery Market

TABLE OF EXHIBITS

EXECUTIVE SUMMARY

• AIM, SCOPE AND ORGANIZATION OF REPORT
• CIENTIFICA NANOTECHNOLOGY MODEL
  • Definitions of Nanotechnologies
  • Major Assumptions
• BACKGROUND

MARKET FORECAST & OVERVIEW

INTRODUCTION TO THE MARKETS

• NANOPHARMACEUTICALS
• NANOTECHNOLOGY IN DRUG DELIVERY
• NANOBIOTECHNOLOGY IN DRUG DELIVERY
• OTHER APPLICATIONS FOR NANOMATERIALS IN THE MEDICAL AND PHARMACEUTICAL SECTOR
• TRENDS AND NEEDS
• ROADMAP
• NANOTECHNOLOGY INFLUENCE IN PHARMACEUTICAL VALUE CHAIN
• ANALYTICAL TECHNIQUES FOR NANOPARTILE DRUG DELIVERY
  • Properties
  • Production Of Nanoparticles
  • Measuring Dispersion Of Nanoparticles
  • Analysis Of Carrier Systems
• NANOPARTICLES AS DRUG CARRIERS
  • What Can Nanoparticles Do In Drug Delivery
  • Overview On The Types Of Nanoparticles In Drug Delivery
  • The First Nanoparticle Drug Delivery System Reaches The Market
  • Present And Future Applications
• PROJECTED PRODUCT PIPELINE FOR NANOPARTICLE IN DRUG DELIVERY MARKET
  • Overview Of Nanoparticle Drug Delivery System (DDS) In Various Applications
  • Available Applications Of Nanopartcile In Drug Delivery

DRUG DELIVERY CHALLENGES -- WHY DRUG DELIVERY & WHY NANOPARTICLES

• THE NEED FOR BETTER DRUG THERAPY
• THE NEED FOR DRUG SOLUBILITY
• THE NEED FOR SITE-SPECIFIC AND ORGAN-SPECIFIC IN FUNCTION

DRIVERS AND OPPORTUNITIES FOR NANOPARTICLE DRUG DELIVERY

• THE AIM OF DRUG TARGETING
• REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING
• MARKET DRIVERS FOR ENHANCED DRUG DELIVERY
• THE ADVANTAGES OF USING POLYMERIC NANOPARTICLES (PNPS) IN DRUG DELIVERY
• EXPANDING GOVERNMENTAL FUNDING DRIVES THE NANOBIOTECHNOLOGY MARKET
• HOW DRUG COMPANIES ARE REACTING TO THIS EXPANSION

FUTURE BARRIERS AND CHALLENGES

• BIG PHARMACEUTICAL COMPANIES RELUCTANT TO INVEST IN UNTRIED TECHNOLOGIES
• LACK OF REGULATORY CASE LAW
• LONG ADMISSION PROCEDURES INCLUDING FOR EXAMPLE SEVERAL CLINICAL TRIALS
• A NEED FOR RAPID SCREENING METHODS
• SCALABILITY OF NANOPARTICLE PRODUCTION
• AN URGENT NEED FOR ANALYTICAL METHODS
• A NEED FOR THE INVESTIGATION OF FURTHER NANOPARTICLES
• THE POTENTIAL TOXICITY OF ENGINEERED NANOPARTICLES IS AN UNSOLVED ISSUE AND STILL NEEDS TO BE DEALT WITH
• THE FUTURE OF NANO AND BIO COLLABORATIONS IS PROMISING

NANOPARTICLE ADDED VALUE IN DRUG DELIVERY

• CASE STUDY -- UNIVERSITY OF MICHIGAN' S NANOPARTICLE-BASED PAIN RELIEF STUDY FOR MILITARY BATTLEFIELD USE
• CASE STUDY -- ACUSPHERE' S HYDROPHOBIC DRUG DELIVERY SYSTEM (HDDS™) FOR REFORMULATION OF HYDROPHOBIC DRUGS
• CASE STUDY -- IMARX' S HYDROPLEX™ PLATFORM FOR DELIVERING HYDROPHOBIC DRUGS
• CASE STUDY - ALPHARX' S NANOPARTICLE DRUG DELIVERY PLATFORM FOR ANTIBIOTIC DRUGS
• CASE STUDY - CYTRX' S RNAI NANOPARTICLE DELIVERY TECHNOLOGY FOR RNAI THERAPEUTICS

INVESTING IN NANOPARTCLE-ENABLED DRUG DELIVERY INDUSTRY

• CASE STUDY - NANOTHERAPEUTICS' COMMERCIALISATION STRATEGY
  • Business Summary
  • Technology Core Competency
  • Commercialisation Strategy
  • Available Market
• CASE STUDY - HOW CAN NANOVINDEX' S NANOPARTICLE HYDROGEL COMPOSITES ADD VALUE FOR DRUG DELIVERY INVESTORS
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Comercialization Strategy
  • Available Market
• CASE STUDY -- KEYSTONE NANO' S MOLECULAR DOTS (MDS) COMMERCIALISATION STRATEGY
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
  • Available Market
  • Intellectual Property
• CASE STUDY - NANOCARRIER' S PROTEINS NANOENCAPSULATION SEEKING OUT BIG BIOTECH BUSINESS
  • Business summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
  • Available Market
• CASE STUDY -- NANOBIOMAGNETICS' BUSINESS MODEL FOR ORGAN-ASSISTING-DEVICE (OAD) TECHNOLOGIES
  • Business Summary
  • Technology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Stratety
  • Intellectual Property
• CASE STUDY - HOW CAN AVIDIMER THERAPEUTICS' AVIDIMERS PLATFORM TECHNOLOGY ADD VALUE FOR DRUG DELIVERY INVESTORS
  • Business Summary
  • Techonology Core Competency
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
• CASE STUDY -- CAPSULUTION' S COMMERCIALISATION STRATEGY FOR LBL-TECHNOLOGYR-BASED DRUG DELIVERY SYSTEMS
  • Business Summary
  • How Nanoparticles Add Value For Investors In Drug Delivery Company
  • Commercialisation Strategy
• CASE STUDY -- ACCESS PHARMACEUTICALS' PRODUCT PIPELINE FOR COBALAMIN™- MEDIATED DISEASE TARGETING
  • Business Summarry
  • Technology Core Competency
  • How Nanoparticle Add Value For Investors In Drug Delivery Company
• CASE STUDY - AZAYA THERAPEUTICS' PRODUCT PIPELINE FOR PROTEIN STABILIZED LIPOSOME (PSL™) NANOTECHNOLOGY
  • Business Summary
  • Technology Core Competency
  • Commercialisation Strategy

NANOPARTICLE DRUG DELIVERY SYSTEM BY DELIVERY METHOD/ROUTES OF ADMINISTRATION

• DELIVERY METHOD
• ORAL ADMINISTRATION
  • Case Study -- Access Pharmaceuticals' Cobalamin™ - Mediated Disease Targeting
  • Case Study - Nanotherapeutics' Nanoparticle Oral Applications
  • Case study - SoluBest' s Solumer™ Technology Platform
• TRANSDERMAL DELIVERY
  • Case Study -- Biophan Technologies' Transdermal Patches By Using Halloysite Nanotubes Technology
  • Case Study -- The Interstitial NanoSystems' Transdermal Nanoparticle Delivery
• INJECTABLE DELIVERY
  • Case Study -- Biophan Technologies' Nanomagnetic Guided Drug Delivery
  • Case Study -- Nanobiotix' s NanoBiodrugsTM
• TOPICAL DELIVERY
  • Case Study -- Starpharma' s VivaGel™
  • Case Study - Nanotherapeutics' NanoDRY™; NanoCOAT™ and NanoQUAD™ Drug Delivery Systems
• INHALED/NASAL/PULMONARY DELIVERY
  • Case Study -- Interstitial NanoSystem' s Pulmonary Nanoparticle Delivery
• IMPLANTABLE DELIVERY
  • Case Study -- Biophan Technologies' Nanomagnetic Drug Delivery: Drug-Eluting Implanted Devices
  • Case Study -- NanoBioMagnetics' Organ-Assisting-Device (OAD) Technologies

NANOPARTICLE DRUG DELIVERY SYSTEM BY THERAPEUTICS

• THERAPY
• CANCER THERAPY
  • Case Study -- Nanocarrier' s Micellar Nanoparticles And Key Delivery Systems
  • Case Study -- Abraxis BioScience' s Nanoparticle Albumin Bound (nabTM) Technology Platform
  • Case Study -- Abraxis BioScience' s AbraxaneR
  • Case Study -- Access Pharmaceuticals, Inc
  • Case Study -- Advance Nanotechnologies' Nanoparticle Composites Drug Delivery System
  • Case Study -- BioAlliance Pharma' s Nanoparticle-based Transdrug® Drug Delivery Platform
  • Case Study -- Cornerstone Pharmaceuticals' Emulsiphan™ Nanoparticle Tumor Targeting Technology
  • Case Study -- Insert Therapeutics' Nanoparticle Mediated Drug Delivery System
  • Case Study -- Keystone Nano' s Molecular Dots (MDs) Drug Delivery Technology
  • Case Study -- Magforce Nanotechnologies' MagForce® Nanoparticles
  • Case Study -- Tempo Pharmaceuticals' Nanocell™ Technology
  • Case Study -- Aphios Corporation' s TaxosomesTM
• VACCINES
  • Case Study -- Biosante Pharmaceuticals' Calcium Phosphate Nanoparticles (CAP)-based Technology
  • Case Study -- NanoMed' s Nanotemplate Engineering Technology
  • Case Study -- Novavax' s Micellar Nano Particles (MNPs), Novasome® Paucilamellar Vesicles And Virus-Like Particle (VLP) Technology
• ANTIBODY
  • Case Study -- Ablynx' s Nanobody® Platform
  • Case Study - NanoViricides' Targeted Anti-Viral Therapeutics Platform
• DNA BASED THERAPY
  • Case Study -- Introgen Therapeutics' Nanoparticle Drug Delivery Technology Platform
  • Case Study -- Asklepios BioPharmaceutical Inc
  • Case Study -- Copernicus Therapeutics' DNA Nanoparticles
  • Case Study -- Calando Pharmaceuticals' Targeted Polymeric Nanoparticle Delivery Systems And Sirna Design
  • Case Study -- Epeius Biotechnologies' Targeted Delivery System (TDS) Technology
  • Case Study -- Intradigm' s Nanoparticle-Based Delivery System
  • Case Study -- Flamel Technologies' Medusa® Delivery Platform
  • Case Study -- Novosom AG' s SMARTICLES® and CAGICLES® Technology
  • Case Study -- Transgenex Nanobiotech' s SiPlex™ Technology

NANOPARTICLE DRUG DELIVERY SYSTEM BY TECHNOLOGY

• NANOPARTICULATE ENCAPSULATION
  • Case Study -- Aquanova' s Nanoparticulate Encapsulation Technology
  • Case Study -- Bio Delivery Sciences International' s Bioral® Encochleation Drug Delivery Technology
  • Case Study -- Capsulution' s LBL-TechnologyR-based Drug Delivery Systems
  • Case Study -- Ceramisphere' s Encapsulation Technology
  • Case Study - Genesegues' Targeted Nanocapsule Technology
  • Case Study - iCeutica' s Encapsulated Organic Nanoparticles (EON™) Platform
  • Case Study - NutraLease' s Nanoencapsulation Technology
• THE DENDRIMER-BASED TARGETED THERAPEUTICS TECHNOLOGY
  • Case Study -- Avidimer Therapeutics' Avidimers
  • Case Study -- Dendritic Nanotechnologies Inc
• LIPOSOMES NANOTECHNOLOGY
  • Case Study -- Azaya Therapeutics' Protein Stabilized Liposome (PSL) Nanotechnology Platform
  • Case Study -- LiPlasome Pharma' s Liposome-based Drug Delivery Platform
• NANOTUBE TECHNOLOGIES
  • Case Study -- Biophan Technologies' Halloysite Nanotube Technologies
  • Case Study -- NanoCyte' s Nanotube Technology-based Drug Delivery System
• NANOSHELL TECHNOLOGY
  • Case Study -- Nanospectra Biosciences' AuroLase™ Cancer Therapy
• NANOPARTICLES COATING TECHNOLOGY
  • Case Study -- Cytimmune' s Colloidal Gold Nanoparticle-Based Delivery Platform
• SILICA-CHITOSAN NANOCOMPOSITE
  • Case Study -- ISTN' s Silica-Chitosan Nanocomposties For Peptic Ulcer Treatment
• NANOCRYSTAL TECHNOLOGY
  • Case Study -- Elan' s NanoCrystal® Technology
• NANOSOME TECHNOLOGY
  • Case Study -- Molecular Therapeutics' Nanosome Platform
• NANOSUSPENSION TECHNOLOGY
  • Case Study -- Baxter BioPharma Solutions' NANOEDGE Dispersion Technology
• POLYMER THERAPEUTICS
  • Case Study - Labopharm' s Polymeric Nano-Delivery System™
  • Case Study -- Intezyne Technologies' IVECT™ Drug Delivery Platform (DDP)
  • Case Study -- Insert Therapeutics' Nanoparticle Mediated Drug Delivery System
• APPENDIX 1: LIST OF NANOPARTICLE DRUG DELIVERY PLATFORMS/TECHNOLOGIES
• APPENDIX 2: NANOPARTICLES IN DRUG DELIVERY PRODUCTS ON THE MARKET OR IN CLINICAL PHASE 1/2/3
• APPENDIX 3: OVERVIEW OF NANOPARTICLE APPLICATIONS IN DRUG DELIVERY
• APPENDIX 4: DRUG DELIVERY COMPANY - COMPANIES WHO PRODUING NANOPARTICLES/TECHNOLOGIES ENABLE BETTER DRUG DELIVERY COMPOUNDS
• APPENDIX 5: DRUG FORMULATION COMPANY - COMPANIES WHO USING NANOPARTICLE-ENABLED FORMULATIONS TO ENHANCE DRUG DELIVERY

• Exhibit 1: Nanoparticle Drug Delivery System By Delivery Method/Routes Of Administration
• Exhibit 2: Nanoparticle Drug Delivery System By Therapeutics
• Exhibit 3: Nanoparticle Drug Delivery System By Technology
• Exhibit 4: Nanoparticle Drug Delivery Technology Used By Drug Formulation Company And Drug Delivery Company By Nation
• Exhibit 5: Phama R&D Spend On Nanotech
• Exhibit 6: Share Of DDS Market
• Exhibit 7: Value Of Nanotechnology Based DDS 2006-2012
• Exhibit 8: Value Of Nanotechnology Based DDS 2006-2015
• Exhibit 9: Value Of Nanotechnology Based DDS 2006-2015
• Exhibit 10: Share of DDS Market
• Exhibit 11: Impace Of Nanotechnologies On Drug Delivery Market 2006-2015
• Exhibit 12: Value Of Nanotparticle Based DDS 2006-2012
• Exhibit 13: Value Of Nanotparticle Based DDS 2006-2015
• Exhibit 14: Value Of Nanostructure Based DDS 2006-2012
• Exhibit 15: Value Of Nanostructure Based DDS 2006-2015
• Exhibit 16: Value Of Dendrimer Based DDS 2006-2012
• Exhibit 17: Value Of Dendrimer Based DDS 2006-2015
• Exhibit 18: Future Medical Practice Estimations Within The Drug Encapsulation/Drug Delivery/Drug Targeting Sector
• Exhibit 19: Estimated Global Production Rates For Various Nanomaterials And Devices (2003- 2004)
• Exhibit 20: Average Technology Targets Of Nanoparticles In The Pharmaceutical Sector
• Exhibit 21: Future Development Of Diagnostics And Therapy By The Means Of Advanced Medical Tools
• Exhibit 22: Nanotechnology Implications On Medical Sector
• Exhibit 23: Pharmaceutical Value Chain And Involvement Of The Four Technologies
• Exhibit 24: Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 25: Typical Image of Colloidal Gold Nanoparticles
• Exhibit 26: FDA Approved Nanoparticle DDS
• Exhibit 27: The Most Appropriate Types of Nanoparticles for Drug Delivery
• Exhibit 28: Overview On The Most Appropriate Types Of Nanoparticles Used In Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 29: Schematic Representation of Polymer Therapeutics Now In or Progressing Towards Clinical Development
• Exhibit 30: Schematic Illustration Of The Therapeutics And Technologies In Clinical Development And/Or On The Market As Treatment For Cancer That Can Be
• Viewed As Nanomedicines
• Exhibit 31: Trend In Issued Patent Involving Nanoparticles For Drug Delivery (1992- 2004)
• Exhibit 32: Goal Of Select Nanoparticle Drug Delivery Patents Issued During 1992-2004
• Exhibit 33: Most Important Applications Of Nanotechnology In The Medical Sector
• Exhibit 34: Typical Configurations Utilised In Nanoparticles Applied To Medical Or Biological Problems
• Exhibit 35: Nanoparticles As Imaging Agents And Drug Carriers
• Exhibit 36: A Representative Photograph of Nanoparticles
• Exhibit 37: World Nanotechnology Industry Focus In 2004 By Sector -- Nanobiotechnology Companies Represent Around 8% Of The Overall Industry
• Exhibit 38: Summary Of Application Areas For Nanoscale Pharmaceuticals And Medicine In Drug Delivery
• Exhibit 39: Trend In Issued Patent Involving Nanoparticle
• Exhibit 40: Expected Evident Bottlenecks In R&D In Drug Encapsulation/Drug Delivery/Drug Targeting
• Exhibit 41: Expected Barriers In The Development Of Particular Types Of Nanoparticles
• Exhibit 42: Specified Expected Barriers In The Development Of Particular Types Of Nanoparticles
• Exhibit 43: The Representation Of HydroPlex™
• Exhibit 44: Slow Releasing Feature Of Encapsulated G-CSF
• Exhibit 45: NanoCarrier Product Pipeline
• Exhibit 46: Business Model of NanoCarrier
• Exhibit 47: NanoBioMagnetics' Investor Business Model
• Exhibit 48: Avidimer Therapeutics' Avidimers Technology
• Exhibit 49: Avidimer Therapeutics' Avidimers Technology
• Exhibit 50: Access Pharmaceuticals Product Pipeline
• Exhibit 51: Azaya Therapeutics Product Pipeline
• Exhibit 52: Access Pharmaceuticals' Cobalamin™
• Exhibit 53: Cobalamin™ Mechanism of Absorption
• Exhibit 54: A Study Of The Oral Administration Of Cobalamin™-Coated Nanoparticles Compared To Uncoated Nanoparticles In Rodents
• Exhibit 55: The Effectiveness Of Oral Drug Delivery Using Cobalamin™-Coated Nanoparticles
• Exhibit 56: Biophan Technologies' Transdermal Patch
• Exhibit 57: Rendering Of Nanotech-Based Bandage
• Exhibit 58: Interstitial NS Transdermal Delivery Applicator Prototype
• Exhibit 59: Biophan Technologies' Nanomagnetic Particle
• Exhibit 60: Injected Drug
• Exhibit 61: Drug Drawn To Tumor
• Exhibit 62: Activating Drug In Tumor
• Exhibit 63: Nanobiotix' s NanoBiodrugsTM
• Exhibit 64: Illustration of Starpharma' s VivaGel™ In Proposed Single-use Applicator Exhibit 65: Interstitial NS Portable Personal Inhaler; Utilises SAW Delivery For Non-Invasive, Pain-Free, User-Controlled Delivery Of Large Molecule Drugs
• Exhibit 66: The Comparison Of Conventional Passive Technology And Biophan Active Technology By Using Nanomagnetic Technology
• Exhibit 67: Polymer Matrix
• Exhibit 68: Particles Loaded On Stent Coating
• Exhibit 69: Drugs Bound To Nanomagnetic Particles
• Exhibit 70: EM Signal Releasing Drugs
• Exhibit 71: Second EM Signal Releasing Drugs
• Exhibit 72: Features Of Nanocarrier' s DDS Technologies
• Exhibit 73: The Core Technology - Micellar Nanoparticles
• Exhibit 74: NanoCarrier' s Micellar Nanoparticles
• Exhibit 75: NanoCapTM
• Exhibit 76: MediCelleTM
• Exhibit 77: NanoCoat System
• Exhibit 78: Unique Benefit Of True Nanoparticles In Oncology: Targeting To Tumors
• Exhibit 79: Chemistry of ProLindac™
• Exhibit 80: Prolindac™ Releases Platinum Much More Rapidly In A Slightly Acidic Environment Compared With An Environment Of The Body' s Normal
• Physiological pH
• Exhibit 81: Emulsiphan™ - Passive Targeting
• Exhibit 82: Emulsiphan™ - Active Targeting
• Exhibit 83: Insert Therapeutics' Cyclosert™ Technology
• Exhibit 84: A Photomicrograph Of A Nano-Composite Particle
• Exhibit 85: A Graphic Representation Of The Molecular Dot
• Exhibit 86: An Overview Of Some Features Of Molecular Dot
• Exhibit 87: Ceramide MDs Kill Drug-Resistant Breast Cancer Cells
• Exhibit 88: BioSante' s Product Pipeline
• Exhibit 89: NanoMed' s Nanotemplate Engineering Technology
• Exhibit 90: Confocal Pictures of DC' s Starined Red With Anti-CD11c And Green Nanoparticles
• Exhibit 91: Novavax' s Micellar Nano Particles (MNPs)
• Exhibit 92: The Comparison of Convential Antibody and Ablynx' s Nanobody
• Exhibit 93: Nanoviricides Dismantling MCMV Seen In TEM
• Exhibit 94: Nanoviricides Product Illustration
• Exhibit 95: NanoViricides Product Pipeline
• Exhibit 96: How BNP Works
• Exhibit 97: AskBio' s Product Pipeline
• Exhibit 98: Nature Compacts DNA
• Exhibit 99: RNA Interference ("RNAi")
• Exhibit 100: Calando' s siRNA Technology
• Exhibit 101: Preclinical Data That Demonstrate Sequence-Specific Gene Inhibition In Tumors From The Systemic Administration Of Targeted Formulations Of Sirna .
• Exhibit 102: qRT-PCR Result Summary
• Exhibit 103: Layers/Functions Of Intradigm' s Nanoparticle
• Exhibit 104: Intradigm Nanoparticle Delivery System for RNAi
• Exhibit 105: Potential Targets For Which Active Sirnas Have Been Identified
• Exhibit 106: Flamel' s Unique Method For The Controlled Release Of Proteins And Peptides
• Exhibit 107: Flamel' s Medusa® Technology
• Exhibit 108: Flamel' s Medusa® Product Pipeline
• Exhibit 109: Novosom AG' s SMARTICLESR
• Exhibit 110: An Animation Of The Process By Which SMARTICLES® Deliver DNA Based Therapeutics Inside A Cell
• Exhibit 111: Novosom' s CAGICLESR
• Exhibit 112: NovaSOL Product Micelle
• Exhibit 113: AQUANOVA Solubilisates (Examples)
• Exhibit 114: AQUANOVA Capsules
• Exhibit 115: Bio Delivery Sciences International' s Bioral® Encochleation Drug Delivery Technology
• Exhibit 116: Determination Of Residual Moisture By Karl-Fischer-Methodd
• Exhibit 117: Overview Of The Encapsulation Process
• Exhibit 118: Overview Of The Complexation Process
• Exhibit 119: How Scalable Technology Addresses Industry' s Key Problems In Biopharmaceutical Delivery
• Exhibit 120: Genesegues' Nanoencapsulated Therapeutic
• Exhibit 121: iCeutica' s EON Process (Example)
• Exhibit 122: NutraLease' s Nanoencapsulation Technology
• Exhibit 123: The Nano-Sized Self-Assembled Structured Liquids (NSSL) Technology
• Exhibit 124: A Phase Diagram Of The Possible Combinations To Form The Nano-Sized Self-Assembled Structured Liquids (NSSL)
• Exhibit 125: Nutralease' s FNV technology
• Exhibit 126: The Release Of Nutralease' Nutraceuticals Into The Membrance Between The Digestive System And The Blood
• Exhibit 127: NutraLease Products
• Exhibit 128: Avidimer Therapeutics' Avidimers
• Exhibit 129: Illustration Of The Dendrimer Compared In Size To Hemoglobin
• Exhibit 130: Priostar™ Product Pipeline
• Exhibit 131: DNT' s PrioFect™
• Exhibit 132: DNT' s STARBURST® Dendrimers
• Exhibit 133: An Example Of Phospholipase A2 Catalyzed Hydrolysis Of A Lipid Membrane Visualized By Atomic Force Microscopy
• Exhibit 134: NanoCyte mode of operation
• Exhibit 135: How Does Colloidal Gold Work
• Exhibit 136: CytImmune Product pipeline
• Exhibit 137: Molecular Therapeutics' Dynamic Nano-Platform
• Exhibit 138: Nanoedge Technology Features
• Exhibit 139: Nanoedge Solid Partilce Technologies
• Exhibit 140: How Do Labopharm' s Polymeric Nano-Delivery System™ Work
• Exhibit 141: Labopharm' s Technologies For In Vivo Delivery
• Exhibit 142: Labopharm' s Therapeutic Pipeline
• Exhibit 143: Labopharm' s Business Development
• Exhibit 144: Intezyne Technologies' IVECT™ Drug Delivery Platform
• Exhibit 145: Insert Therapeutics' Cyclosert™ Polymers
• Exhibit 146: Insert Therapeutics' Cyclosert™ Multiple Formulations